Editas Medicine (EDIT) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.15

Estimate

-$0.21

Surprise

+27.2%

Revenue (period 2026-09-30)

$10.4M

Score at report (before → after)

5.6 → 5.7/10

Revenue source: xbrl.

Editas Medicine (EDIT) reported a narrower loss than forecast — adjusted EPS of -$0.15 against the -$0.21 estimate (a 27.2% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.6/10) to Sell at 5.7/10 after the report.

• Editas Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates — fiscal.ai, 2026-11-09
• Editas Medicine Q3 EPS $(0.15) Beats $(0.18) Estimate, Sales $10.365M Beat $4.460M Estimate — benzinga, 2026-11-09

TrendMatrix currently rates EDIT Sell at 5.4/10.

3 of the last 4 quarters beat the estimate; this quarter's +27.2% surprise compares with a +34.5% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$2.50

Price target

$5.31

Stop

$2.33

Upside to target

+112.4%

Reward-to-risk

7.5:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$422.3M

P/E (fwd)

-3.7

52-week range

$1.66–$3.94

Off 52-week high

36.5%

RSI (14)

50

Volume vs avg

0.43×

Score today

5.4/10